AEON Biopharma reports Q2 2026 results, cites new financing and FDA meeting on ABP-450

AEON Biopharma, Inc. reported financial results for the second quarter ended June 30, 2026, in an 8-K filed August 12, 2026. The company reported cash and cash equivalents of $3.4 million as of June 30, 2026, which does not include approximately $13.6 million of net proceeds from an underwritten public offering completed in July 2026.¹ Counting those proceeds, the company said cash and cash equivalents are expected to fund operations into the first quarter of 2027, supporting continued work on its ABP-450 program.¹

The July offering also carried milestone warrants. The underwritten public offering brought in net upfront proceeds of approximately $13.6 million, with the potential for up to an additional $34.0 million in gross proceeds if the milestone warrants issued in the deal are exercised in full for cash.¹

On the regulatory side, AEON said it met with the FDA earlier in the year. The company held a Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA during the first quarter of 2026, during which the agency reviewed AEON's proposed strategy for showing analytical similarity under the 351(k) biosimilar pathway and gave feedback on the company's planned approach for ABP-450.¹ The FDA also noted the scientific difficulty of characterizing the 900 kDa botulinum neurotoxin complex given its size and potency, while offering feedback on AEON's proposed testing plan.¹

AEON said it now awaits a planned BPD Type 2b interaction with the FDA in the second half of 2026, which it expects will help shape the next phase of ABP-450 development, including requirements for clinical pharmacology and comparative clinical studies.¹

Separately, the company said it regained full compliance with NYSE American continued listing requirements on August 3, 2026, resolving previously identified deficiencies.¹